{"id":2242,"date":"2024-04-26T13:09:43","date_gmt":"2024-04-26T13:09:43","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2242"},"modified":"2024-04-26T13:09:44","modified_gmt":"2024-04-26T13:09:44","slug":"fda-approves-pfizers-beqvez-gene-therapy-for-hemophilia-b-a-milestone-in-rare-disease-treatment","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/26\/fda-approves-pfizers-beqvez-gene-therapy-for-hemophilia-b-a-milestone-in-rare-disease-treatment\/","title":{"rendered":"FDA Approves Pfizer&#8217;s Beqvez Gene Therapy for Hemophilia B: A Milestone in Rare Disease Treatment"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Pfizer&#8217;s Breakthrough Therapy Offers Hope to Patients Despite Hefty Price Tag<\/h4>\n\n\n\n<p>The Food and Drug Administration&#8217;s approval of Pfizer&#8217;s (PFE) Beqvez marks a significant milestone in the treatment landscape for hemophilia B, a rare genetic bleeding disorder affecting over 7,000 individuals in the U.S. With Beqvez being Pfizer&#8217;s first-ever gene therapy to receive clearance in the U.S., the drug represents a leap forward in addressing unmet medical needs for patients with moderate to severe hemophilia B.<\/p>\n\n\n\n<p>Beqvez, designed as a one-time treatment, aims to enable patients to produce factor IX themselves, thereby preventing and controlling bleeding episodes associated with hemophilia B. This novel approach offers an alternative to the often-cumbersome standard treatment regimen involving frequent factor IX infusions.<\/p>\n\n\n\n<p>Dr. Adam Cuker, director of Penn&#8217;s Comprehensive and Hemophilia Thrombosis Program, hailed Beqvez as potentially transformative for appropriate patients, reducing both the medical burden and treatment disruptions over the long term.<\/p>\n\n\n\n<p>Despite its promise, Beqvez comes with a hefty price tag of $3.5 million before insurance and rebates, positioning it as one of the most expensive drugs in the U.S. Pfizer&#8217;s investment in gene and cell therapies, including Beqvez, underscores the company&#8217;s commitment to advancing innovative treatments for rare diseases and solidifying its position in the evolving healthcare landscape.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/26\/biodexas-acquisition-of-erapa-marks-milestone-in-fap-treatment-development\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Biodexa\u2019s Acquisition of eRapa Marks Milestone in FAP Treatment Development<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer&#8217;s Breakthrough Therapy Offers Hope to Patients Despite Hefty Price Tag The Food and Drug Administration&#8217;s approval of Pfizer&#8217;s (PFE) Beqvez marks a significant milestone in the treatment landscape for hemophilia B, a rare genetic bleeding disorder affecting over 7,000 individuals in the U.S. With Beqvez being Pfizer&#8217;s first-ever gene therapy to receive clearance in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[361,309],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2242"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2242"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2242\/revisions"}],"predecessor-version":[{"id":2244,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2242\/revisions\/2244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2242"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}